Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25946918 | 0.92 | KMT2A (0.38) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL26800277 | 0.87 | HSP90AA1 (0.38) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL24448756 | 0.78 | MEN1 (0.45) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL25948762 | 0.74 | KAT8 (0.48) | — | |
| SCHEMBL24448755 | 0.70 | AADAT (0.40) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL24449893 | 0.70 | HSP90AA1 (0.45) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL4552450 | 0.67 | MEN1 (0.45) | MEN1NPC1RAB9AKMT2AHSP90AA1 | |
| SCHEMBL19170474 | 0.66 | MEN1 (0.52) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL19716279 | 0.64 | MEN1 (0.47) | SMN1; SMN2MEN1NPC1RAB9AKMT2A | |
| SCHEMBL370625 | 0.63 | MEN1 (0.44) | MEN1NPC1RAB9AKMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | SMN1; SMN2 3017/4885MEN1 1860/4885NPC1 329/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | SMN1; SMN2 3017/4885MEN1 1860/4885NPC1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.